Evidence map›Paper›PMID 33356689›Full record

ArticleLeukemia & lymphoma2021

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.

Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep Dave, Prithviraj Bose, Mary Beth Tombes, Ellen Shrader, Wen Wan, Dipankar Bandyopadhyay, Caryn Weir and 6 more

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Beata HolkovaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Danielle ShaferMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Victor YazbeckMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Sandeep DaveDepartment of Medicine, Duke University, Durham, NC, USA.
Prithviraj BoseMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0002-4343-5712
Mary Beth TombesMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Ellen ShraderMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Wen WanMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Dipankar BandyopadhyayMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Caryn WeirMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Elizabeth B CollinsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Amanda GarnettMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Maciej KmieciakMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
John D RobertsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven GrantMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
Virginia Commonwealth University · USDuke University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
Targeting Multiple Myeloma with Smac-mimetics and HDAC InhibitorsR01CA205607 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2016 to 2020
$1.6M
Proteasome/HDAC Inhibition in Leukemia/MDS; Phase I Trial and Correlative StudiesRC2CA148431 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2009 to 2010
$1.2M
NCATS NIH HHS UL1 TR002649NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA205607NCI NIH HHS RC2 CA148431
6 · The paper itself

Abstract

We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesAdultAntineoplastic Combined Chemotherapy ProtocolsBortezomibHumansHydroxamic AcidsSulfonamidesTreatment OutcomebelinostatBortezomibHydroxamic AcidsSulfonamidesAcute leukemiabelinostatbortezomibmyelodysplastic syndromephase 1 clinical trial

Identifiers

PMID33356689
PMCPMC8106643
OpenAlexW3115682482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.